Kainate receptor Inhibitors
1 drugsAbout Kainate receptor
Kainate receptors are ionotropic glutamate receptors involved in excitatory neurotransmission in the central nervous system. Activated by glutamate and kainic acid, they participate in various physiological processes by modulating neuronal excitability.
Kainate receptors are potential drug targets due to their role in neuronal signaling pathways implicated in various diseases. Currently, there is no genetic evidence directly linking Kainate receptors to specific diseases, but their role in modulating neuronal excitability makes them attractive targets.
There is one FDA-approved drug, QSYMIA, targeting Kainate receptors for metabolic indications. QSYMIA, developed by VIVUS LLC, was first approved in 2012 and remains the only approved drug in this space.
Top Kainate receptor Drugs
VIVUS LLC is the only company with an approved drug targeting Kainate receptors.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in the target's tractability.
Kainate receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Kainate receptor, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Kainate receptor Clinical Trials 20 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Kainate receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 2 | 1 | 0 | 67% |
| Phase 2 | 8 | 4 | 2 | 2 | 67% |
| Phase 3 | 2 | 1 | 0 | 1 | 100% |
| Phase 4 | 7 | 6 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Kainate receptor Drug Approval Timeline (2012 - 2012)
The first and only drug, QSYMIA, was approved in 2012.
The lack of recent approvals suggests a saturated market or challenges in developing new Kainate receptor-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 18 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Kainate receptor. A trial counts if an approved drug acting on Kainate receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.